Making the connections to reduce risk: cardiovascular, renal and metabolic benefits of SGLT2 inhibitors in T2D

Chair: Janaka Karalliedde (GBR)

12:30 – 12:35Opening the conversation: the priorities in comprehensive T2D careJanaka Karalliedde (GBR)
12:35 – 12:45Connecting the dots: current guidelines for the management of T2DGian Paolo Fadini (ITA)
12:45 – 13:00Beyond glucose control: cardiovascular and renal benefits of SGLT2 inhibitorsShelley Zieroth (CAN)
13:00 – 13:15Synergies for optimal outcomes: the new era of T2D treatmentAna Cebrián (ESP)
13:15 – 13:30Q&A and closeAll faculty
Boehringer Ingelheim Logo
  • Monday, 28 September 2026
  • 12:30 - 13:30 CEST
  • Berlin Hall